Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ERBB4 over exp
Gene Variant Detail

ERBB4 over exp (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB4 over exp marginal zone lymphoma resistant Idelalisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line was found to have ERBB4 overexpression following acquired resistance to Zydelig (idealisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Umbralisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Ukoniq (umbralisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Duvelisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Copiktra (duvelisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Copanlisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Aliqopa (copanlisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Zanubrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Brukinsa (zanubrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Acalabrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Calquence (acalabrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Pirtobrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Idelalisib + Rituximab Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to combination treatment with Rituxan (rituximab) and Zydelig (idelalisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma sensitive Idelalisib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Tykerb (lapatinib) restored sensitivity to Zydelig (idealisib) and led to synergistic inhibition of viability in a marginal zone lymphoma cell line with ERBB4 overexpression in culture (PMID: 38052765). 38052765